|
| Thursday, February 5, 2026 |
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share |
| According to the disclosure of interests information released by the Hong Kong Stock Exchange, GIC Private Limited made its equity investment in Ascletis Pharma by acquiring 64,128,000shares at a price of HKD12.18per share, involving a total consideration of approximately HKD781.08million (equivalent to approximately USD100.01 million). more info >> |
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司入股6412.8萬股 涉資約1億美元 |
| 根據香港聯交所披露的文件，新加坡政府投資公司（GIC Private Limited）入股歌禮製藥，以每股均價12.18 港元，買入 64,128,000 股普通股股份，合計涉資約7.81億港元，折合約1億美元。 more info >> |
|
|
歌礼制药-B（01672）获新加坡政府投资公司入股6412.8万股 涉资约1亿美元 |
| 根据香港联交所披露的文件，新加坡政府投资公司（GIC Private Limited）入股歌礼制药，以每股均价12.18 港元，买入 64,128,000 股普通股股份，合计涉资约7.81亿港元，折合约1亿美元。 more info >> |
|
| Wednesday, August 1, 2018 |
|
|
Ascletis Successfully Listed on the Main Board of HKEX |
| Recently, following the official implementation of the revised listing rules by the Hong Kong Stock Exchange (HKEX), the Hong Kong capital market has been opened up further, welcoming listing applications from several biotechnology companies. more info >> |
|
|
中國首個原研全口服丙肝治愈方案上市申請獲受理 |
| 歌禮今日宣布，公司向國家藥品監督管理局遞交的中國首個原研全口服丙肝治愈方案上市申請已獲受理。 more info >> |
|
|
中国首个原研全口服丙肝治愈方案上市申请获受理 |
| 歌礼今日宣布，公司向国家药品监督管理局递交的中国首个原研全口服丙肝治愈方案上市申请已获受理。 more info >> |
|
|
Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA |
| Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA). Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China. more info >> |
|
| Tuesday, July 31, 2018 |
|
|
歌禮原研抗丙肝創新藥戈諾衛成績非凡 |
| 歌禮2018年7月30日宣布，戈諾衛（達諾瑞韋）III期臨床研究在7月29日結束的中華醫學會第十五次全國感染病學學術會議上獲得大會一等獎。 more info >> |
|
|
歌礼原研抗丙肝创新药戈诺卫成绩非凡 |
| 歌礼2018年7月30日宣布，戈诺卫（达诺瑞韦）III期临床研究在7月29日结束的中华医学会第十五次全国感染病学学术会议上获得大会一等奖。 more info >> |
|
|
Ascletis-developed Ganovo Acquired Extraordinary Achievement |
| Ascletis announced on July 30, 2018 that the Ganovo phase III clinical study won the top clinical research award at the 15th National Congress of Chinese Society of the Infectious Disease of the China Medical Association. more info >> |
|
|
|
|
